KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $32.8 billion.

  • Teva Pharmaceutical Industries' Total Liabilities fell 229.72% to $32.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.8 billion, marking a year-over-year decrease of 229.72%. This contributed to the annual value of $32.8 billion for FY2025, which is 229.72% down from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Total Liabilities stood at $32.8 billion, which was down 229.72% from $32.6 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Total Liabilities high stood at $38.0 billion for Q1 2021, and its period low was $32.1 billion during Q1 2025.
  • Moreover, its 5-year median value for Total Liabilities was $35.3 billion (2023), whereas its average is $35.1 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Total Liabilities soared by 192.17% in 2024, and later plummeted by 875.39% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Total Liabilities stood at $36.4 billion in 2021, then decreased by 2.77% to $35.4 billion in 2022, then dropped by 0.17% to $35.4 billion in 2023, then dropped by 4.94% to $33.6 billion in 2024, then dropped by 2.3% to $32.8 billion in 2025.
  • Its last three reported values are $32.8 billion in Q4 2025, $32.6 billion for Q3 2025, and $33.3 billion during Q2 2025.